IDEAYA Biosciences Inc (NAS:IDYA)
$ 37.71 -0.74 (-1.92%) Market Cap: 2.85 Bil Enterprise Value: 2.16 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 37/100

IDEAYA Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 04:15PM GMT
Release Date Price: $35.89 (-1.89%)
Anupam Rama J.P. Morgan Securities LLC;Analyst

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama, I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno, Mary Hall, Priyanka Grover. Our next presenting company is IDEAYA. And presenting on behalf of the company, we have CEO, Yujiro Hata. Yujiro?

Yujiro Hata
IDEAYA Biosciences Inc - President, Chief Executive Officer, Director

Oh great. Well thank you so much, everyone for attending today's presentation, and thank you also for JPMorgan for the opportunity to present today. So earlier on Sunday, we provided several key program updates, which I'll highlight today. In addition, we did give our 2024 corporate guidance.

In 2024 we believe there's going to be a big opportunity for darovasertib. In particular, a significant focus on our Phase 2 company-sponsored neoadjuvant uveal melanoma trial. In addition, we've given specific guidance of our target to present Phase 2 clinical efficacy data in the middle of this year.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot